Bellevue Group AG
Q3 2022 13F-HR Holdings
Net value change ($000)
-106,488
(-1.5%)
New positions
15
Sold out positions
11
Turnover %
1.8%
Sector allocation + QoQ delta (equities-only)
Holdings aggregated across other managers listed in the original SEC filing. View detailed breakdown
Snapshot: Change Analysis
Compared to Q2 2022
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| IONS | 56,639 | 15.6% |
| ALNY | 37,169 | 24.1% |
| Myovant Sciences Ltd. | 32,610 | 44.3% |
| RLAY | 26,521 | 39.3% |
| RVMD | 26,353 | 40.0% |
| NBIX | 25,982 | 9.4% |
| CLDX | 25,660 | 102.9% |
| AGIO | 24,711 | 27.4% |
| Axonics, Inc. | 23,363 | 17.8% |
| Sage Therapeutics, Inc. | 20,298 | 21.1% |
Top Reduces (Value $000, Stocks/ETFs)
| Radius Health, Inc. | -91,220 | -100.0% |
| MRNA | -40,877 | -18.1% |
| Intra-Cellular Therapies, Inc. | -36,271 | -19.0% |
| JAZZ | -33,393 | -23.3% |
| INCY | -27,815 | -13.2% |
| ABT | -19,095 | -11.2% |
| ARGX | -17,783 | -5.1% |
| TFX | -17,256 | -73.1% |
| ALGN | -16,486 | -51.5% |
| ISRG | -14,178 | -7.8% |
Instrument mix + QoQ Δ (ex-options)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|